Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424

[2] Ferlay J(2022)Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer Best Pract Res Clin Obstet Gynaecol. 78 86-102

[3] Soerjomataram I(2018)Hyperthermic intraperitoneal chemotherapy in ovarian cancer N Engl J Med. 378 230-240

[4] Vos LMC(2022)NCCN guidelines® insights: ovarian cancer, version 3.2022 J Natl Compr Canc Netw. 20 972-980

[5] Aronson SL(2020)Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: a single center, real-life experience Cancer 126 5256-5262

[6] van Driel WJ(2015)FIGO committee on gynecologic oncology staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the international federation of gynecology and obstetrics (FIGO) Obstet Gynecol. 126 171-174

[7] vanDrielWJ KooleSN(2006)A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study Ann Surg Oncol. 13 1156-1161

[8] Sikorska K(2021)Laparoscopy technique in the setting of peritoneal metastases to avoid port site relapse Surg Oncol. 37 101543-1282

[9] Armstrong DK(2017)Enhanced recovery after surgery for advanced ovarian cancer: a systematic review of interventions trialed Int J Gynecol Cancer. 27 1274-6

[10] Alvarez RD(2008)Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma Am J Obstet Gynecol. 199 642.e1-1454

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424

[2] Ferlay J(2022)Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer Best Pract Res Clin Obstet Gynaecol. 78 86-102

[3] Soerjomataram I(2018)Hyperthermic intraperitoneal chemotherapy in ovarian cancer N Engl J Med. 378 230-240

[4] Vos LMC(2022)NCCN guidelines® insights: ovarian cancer, version 3.2022 J Natl Compr Canc Netw. 20 972-980

[5] Aronson SL(2020)Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: a single center, real-life experience Cancer 126 5256-5262

[6] van Driel WJ(2015)FIGO committee on gynecologic oncology staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the international federation of gynecology and obstetrics (FIGO) Obstet Gynecol. 126 171-174

[7] vanDrielWJ KooleSN(2006)A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study Ann Surg Oncol. 13 1156-1161

[8] Sikorska K(2021)Laparoscopy technique in the setting of peritoneal metastases to avoid port site relapse Surg Oncol. 37 101543-1282

[9] Armstrong DK(2017)Enhanced recovery after surgery for advanced ovarian cancer: a systematic review of interventions trialed Int J Gynecol Cancer. 27 1274-6

[10] Alvarez RD(2008)Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma Am J Obstet Gynecol. 199 642.e1-1454